The purpose of this study is to evaluate the effect of a PCSK9 inhibitor called alirocumab on the occurrence of cardiac events such as myocardial infarction (heart attack), death and the need for coronary artery bypass surgery or coronary intervention. Patients enrolled who have had had a myocardial infarction heart attack or a severe attack of angina during the past 11 months.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
180-13Principal Investigator: Conducted at:
Long Beach MemorialCurrently enrolling additional patients:
Male & Female